Introduction
Autoimmune epilepsy is an under-recognized condition without standardized management guidelines [1] . However, identifying an underlying autoimmune etiology for epilepsy is critical, as these patients may remain refractory to conventional antiseizure medications (ASM) . A large population-based study (n > 2,000,000) showed that patients with autoimmune disease constituted 17.5% of patients with epilepsy, and that the presence of an autoimmune disorder may contribute to a fourfold increased risk of epilepsy [2] . It is reasonable to have a high index of suspicion for autoimmune epilepsy in these patients [3] . Despite increased recent research interest, no clear guidelines exist for the diagnosis or management of autoimmune epilepsy. Various immunomodulatory therapies, including steroids, intravenous immunoglobulin (IVIG), cyclophosphamide, and rituximab have been utilized to achieve seizure control in ASM-resistant patients [4] .
Epilepsy is a recognized manifestation of autoimmune encephalitis [5] . Autoantibodies associated with encephalitides, as well as with epilepsy, include those directed against neuronal intracellular antigens or neuronal cell surface antigens. Neuronal cell surface antigens include voltage gated potassium channel complex (VGKc), NMDA and AMPA glutamate receptors, and GABA receptors, whereas intra-neuronal autoantibodies include antiHu, anti-Ma2, and anti-CRMP-5 [3, 6, 7] . Intraneuronal antibodies have been shown to be a marker of underlying malignancy [8] . Neuronal cell death associated with these antibodies has shown to be T-cell mediated, rather than direct antibody-mediated as with surface antigen-related autoimmunity [9] [10] [11] .
Our study is a retrospective case series of 34 patients with varied clinical and electrographic characteristics who were Purpose: Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and evaluate the effect of early diagnosis and treatment on reduction of seizure frequency. Methods: Observational retrospective case series, conducted using electronic medical data from two teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were selected based on the presence of laboratory evidence of autoimmunity. Results: 34 hospitalized patients who presented predominantly due to seizures with concern for autoimmune etiology were identified. Mean age of patients was 44.94 years and 64.7% were males. Autoimmune antibodies were detected in 76.5% (26) of patients as follows: VGKc (8); NMDA-R (7); antithyroid (5); GAD (4); GABA B (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 9 patients had an underlying malignancy. 94.1% (32) patients received immunomodulation, as follows: high dose corticosteroids (96.8%), plasmapheresis (62.5%), IVIG (34.4%), rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). 63.3% (19) participants achieved 50% seizure reduction (Responder Rate) at first clinic visit. Patients without malignancy had better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to immunomodulation (p < 0.005) was significantly lower among patients who achieved responder rate (RR). Conclusion: This study highlights certain important clinical and electrographic aspects of autoimmune epilepsy, and the significance of early diagnosis and initiation of immunomodulatory therapy.
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diagnosed with autoimmune epilepsy. It contributes to the currently sparse literature characterizing autoimmune epilepsy and its management. We hypothesized that that early diagnosis, as well as early treatment initiation, would lead to significant reduction in seizure frequency, as measured by responder rate (RR). Additionally we also hypothesized that the patients with underlying malignancy would respond less favorably to immunomodulatory therapy compared to those without cancer.
Methods
We conducted a retrospective chart review using data from two teaching hospitals primarily managing adult patients [Parkland Memorial Hospital (PMH) and UT Southwestern University Hospital (UTSW)]. Clinical data was collected from January 2008 through December 2013. Institutional Review Board approval and site clearance from both sites were obtained. Patients were screened by selecting charts with a primary diagnosis corresponding to the ICD-9 code of encephalitis (323.0, 323.9) during the hospital encounter. Cases included in the study were patients presenting with new onset electrographic seizure activity, plus at least two of the following: (1) CSF findings consistent with inflammation (elevated CSF protein >50 and/or lymphocytic pleocytosis), (2) brain MRI showing signal changes consistent with limbic encephalitis, (3) autoimmune/paraneoplastic antibodies in serum or CSF which have been associated with autoimmune encephalitis in previous studies (any neuronal nuclear/cytoplasmic antibody such as anti-Hu or anti-CRMP-5, any neuronal membrane antibody including anti-VGKC, anti-NMDA-R, anti-GABA B -R, anti-ganglionic AChR, or anti-glutamic acid decarboxylase (GAD) antibody), (4) new onset seizure responding to immunomodulatory therapies. Cases were excluded if there was evidence of another identified cause of the patient's seizures: (1) Presence of CSF viral/bacterial/fungal antigens or antibodies or DNA PCR which could explain underlying acute inflammatory brain parenchymal changes, (2) Presence of metabolic abnormalities which could have precipitated seizures (severe renal or hepatic failure, malignant hypertension, severe hypo/ hyperglycemia), (3) Presence of brain structural lesions such as stroke, tumor, traumatic lesions, heterotopias, mesial temporal sclerosis, vascular malformation, abscess or infectious lesion which could have precipitated the presenting seizures.
Cases selected based on inclusion and exclusion criteria that did not have a pre-specified antibody were further divided based on the presence or absence of high titers of thyroid peroxidase (TPO) antibodies (>100 IU/ml). Anti-TPO antibody was not included in the pre-specified inclusion criteria, due to lack of specificity of this antibody for autoimmune encephalopathy [12] .
Collection of patient health information, including epidemiological and demographic variables [age, sex, race, location (county hospital or university hospital), clinical presentation, symptoms, duration of presentation to diagnosis, laboratory tests, cerebrospinal fluid (CSF) analysis, type of antibodies, electro-encephalography (EEG) findings, imaging (MRI), immunosuppressive therapies used, and neurological outcome] was performed by manual search of the electronic medical record system at both institutions (PMH and UTSW). A reduction of 50% seizure frequency was considered a favorable clinical outcome, and was termed the ''Responder Rate'' (RR).
Categorical variables were analyzed using Chi Square. Assessment of normative distribution of independent variables was performed by Shapiro-Wilk test of normality. Normative data was analyzed by independent t-test, and non-normative data was analyzed using Mann-Whitney U test. Due to multiple comparisons, Bonferroni correction was utilized; p-value of < 0.05 was considered statistically significant. Binomial logistic regression was utilized to adjust for baseline characteristics.
Results
34 patients with autoimmune epilepsy were identified. (8); anti-NMDA-R in 20.6% (7); anti-thyroid/TPO in 14.7% (5); anti-GAD in 11.8% (4); anti-GABA B in 5.9% (2) . Nine patients (26.5%) included in the study had an underlying malignancy; 2 ovarian teratomas, 2 breast cancer, 1 adenocarcinoma of the lung, 1 small cell lung cancer, 1 testicular cancer, 1 papillary thyroid cancer and 1 thymoma. Median duration of symptom onset to EEG was 22 days (3-96 days), symptom onset to diagnosis was 32 days (5-393 days), symptom onset to brain MRI brain was 33 days (2-309 days), and symptom onset to immunomodulatory therapy initiation was 35 days (range 8-396 days). Median time to clinic follow-up after hospital discharge was 53.5 days (19-101 days). Electrographic seizures were documented in 64.7% (22) of patients in our institution, while the remainder of the patients had evidence of electrographic seizures at an outside hospital prior to transfer to our institution. Of the 34 patients included, 22 (64.7%) had unilateral and 4 (11.8%) had bilateral temporal lobe onset, while 8 (23.5%) had extra-temporal onset/multiple ictal foci. 29.4% (10) patients had only electrographic seizures, without clinical correlate; 44.1% (15) patients were discovered to have focal status epilepticus on vEEG monitoring. Interictal discharges were present in 79.4% (27) of cases. Median number of seizures during initial prolonged vEEG monitoring was 8 (range 0-48); median number of anti-seizure medications used was 2 (range 1-5). 70.6% (24) patients had MRI changes concerning for autoimmune encephalitis (Fig. 1) .
63.3% (19) of patients had 50% reduction in seizure frequency (RR) at the first clinic visit, following inpatient management of acute episode. 6 (17.6%) patients had complete resolution of seizures on initial clinic follow up. 94.1% (32) patients received immunomodulatory therapies, including high dose corticosteroids (96.8%), plasmapheresis (62.5%), and IVIG (34.4%). 9 (28.1%) patients received only high dose corticosteroids as immunomodulatory therapy for acute management of recurrent seizures, whereas the remaining patients received a combination of corticosteroids with plasmapheresis and/or IVIG [Corticosteroids + plasmapheresis: 12(35.3%), Corticosteroids + IVIG + plasmapheresis: 8 (25%), Corticosteroids + IVIG 3 (9.4%)]. Several patients also received additional immunomodulation in the form of chemotherapeutic agents, including rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). There was no significant difference in RR at first clinic visit with use of different immunomodulatory regimens.
Among the two patients who did not receive immunomodulation, one patient was started on levtriacetam 500 mg BID with good seizure control; his evaluation was remarkable for CSF pleocytosis and FLAIR hyperintesity involving left medial temporal lobe, but no antibody was indentified. The second patient had anti-GAD antibody, and also showed significant improvement in seizure frequency following initiation of levtriacetam.
There was no significant difference in seizure reduction based on gender, race, age, hospital category (county or university hospital), presenting symptom (behavior change, memory loss, seizure, altered mental status, speech changes, or movement disorder), or type of antibody detected. But, patients without an underlying malignancy had a better RR (p < 0.05). Having antibodies directed against neuronal cell membrane antigens versus anti-GAD or anti-thyroid antibodies did not affect RR significantly. Duration of symptom onset to diagnosis (median duration: 16 days versus 95 days, U = 48.00, p < 0.005) and duration of symptom onset to immunomodulatory therapy (median duration: 19 days versus 100.5 days, U = 43.00, p < 0.005) was also significantly lower among patients who had 50% reduction of seizures. Time from symptom onset to EEG (U = 56.00, p < 0.05), symptom onset to Lumbar Puncture (U = 56.50, p < 0.05) and symptom onset to MRI (U = 41.00, p < 0.005) was significantly lower among patients who had a favorable Responder Rate. Even after adjustment of baseline characteristics (age, gender, race, type of antibody), the time from symptom onset to diagnosis (CI 0.82-0.98, p < 0.05) and time from symptom onset to immunomodulation (CI 0.83-0.99, p < 0.05) continued to be significantly lower in the group with a favorable Responder Rate. There was no significant relationship between average pre-treatment seizure frequencies or number of AEDs used, or other clinical measures (CSF pleocytosis, interictal discharges or ictal EEG pattern, or pattern of MRI changes) and RR.
Discussion
Our study supports the value of early diagnosis and immunomodulation in reducing seizure frequency in patients with autoimmune epilepsy, who are often resistant to conventional ASM. In some of these refractory epilepsies, identification of an underlying auto-immune etiology and initiation of immunomodulation might ultimately prevent unnecessary surgical intervention. Additionally, we also found that patients with autoimmune epilepsy without underlying malignancy are more likely to experience seizure reduction with therapy. Prevalence of autoimmune epilepsy secondary to neuronal cell surface antigen specific antibodies appears to be significantly higher than intra-neuronal antigen specific antibodies (typical paraneoplastic antibodies).
Our work builds on a similar recent study [3] . Quek et al. published a retrospective observational case series of 32 patients with autoimmune epilepsy, the majority of whom had VGKc autoantibodies. The clinical characteristics of our study population differed from theirs somewhat, as our two largest antibody subgroups included VGKc and NMDA-R. We also compared these two subgroups in regards to clinical, electrographic features and clinical outcome but found no significant difference. The most common presenting symptom in our patients was seizure, as in theirs. None of our cases underwent epilepsy surgery, though several patients in their study did.
Quek et al. suggested some general diagnostic characteristics that increase clinical suspicion for autoimmune epilepsy, which are here confirmed by our study, including high seizure frequency or variability, ASM resistance, and history of autoimmunity or malignancy. Most of the antibody mediated encephalitides are associated with temporal lobe epilepsy, while antibodies to Leucine-rich, glioma inactivated 1 (LGI-1), a VGKc component, may be associated with a facio-brachial dystonic seizure syndrome [3, 7, 13] . Only one out of eight VGKc positive patients in our study had faciobrachial dystonic seizures. The majority of our patients had unilateral temporal lobe focus of epilepsy. Though previous studies have documented EEG findings such as 'extreme delta brush' in patients with NMDA-R antibody mediated encephalitis, no antibody specific inter-ictal changes were found among our patients [14] . Some patients have clinical, electrographic, radiographic, and CSF characteristics consistent with autoimmune epilepsy, even without underlying antibody positivity, which may reflect the yet undiscovered array of neuronal antibodies that could result in autoimmune epilepsy. Clinicians should, therefore, consider the diagnosis of autoimmune epilepsy even if the CSF or serum antibody panel is negative, based on the overall clinical presentations including the EEG, MRI, CSF and other laboratory findings [15, 16] . To manage autoimmune epilepsy, Bien et al. have suggested treating any underlying malignancy, then proceeding with IV corticosteroid initiation (methylprednisolone), followed by cyclophosphamide or rituximab if the epilepsy syndrome proves to be resistant [17] . Even though the immunomodulatory regimen varied in the patients included in our study, the majority of the patients received IV corticosteroids as the initial therapy followed by plasmapheresis or IVIG. In our study, only those patients who remained refractory to corticosteroids or plasmapharesis or both modalities, received chemotherapeutic agents such as rituximab or cyclophosphamide. Nevertheless, our study demonstrates that early initiation of treatment leads to better overall RR, a common marker of the success of antiepileptic treatment.
Limitations of this study include the retrospective design and the small study population. Limited numbers made it difficult to assess statistical significance in some variable associations. Despite a thorough search of electronic medical records, some autoimmune epilepsy patients could have been missed, especially if coding or chart diagnosis was not correctly performed. Since only 9 patients underwent PET scans in our study, underlying malignancy could have been missed. For twelve patients included in our study no electrographic seizures were recorded in our institution (PMH or UTSW), data collection was based on EEG reports and medical records from out-side facility.
Conclusion
This study highlights important clinical aspects of autoimmune epilepsy. Early diagnosis is likely the most critical step for affected individuals, and the identification of the common clinical and electrographic presentations provided herein may aid in that diagnosis. Furthermore, our study demonstrates that timely initiation of immunomodulatory agents helps reduce seizure frequency and that the patients without an underlying malignancy tend to respond better to such therapy. Future prospective studies will be necessary to determine the ideal immunomodulatory treatment regimen for patients based on clinical presentation and antibody-type. 
Funding
None.
